Merck & Co Inc (NYSE: MRK) and its collaborating partner Ridgeback Biotherapeutics LP reported preliminary results from Phase 2a study evaluating molnupiravir, an experimental antiviral drug against COVID-19.
- The antiviral has shown positive effects with a significant reduction in the infectious virus in COVID-19 patients after five days of treatment.
- If results from further ongoing testing show the drug can treat COVID-19 patients exhibiting symptoms, it could be the first oral antiviral to fight the infection, the Wall Street Journal reports.
- The full study results remain blinded and will be shared later as they become available.
- Merck is also working on one more COVID-19 treatment called MK-711.
- The first results of the trials show a reduction of more than 50% in the risk of death or respiratory failure in hospitalized patients.
- Last month, it announced that the FDA asked for additional data beyond the study conducted by OncoImmune.
- Price Action: MRK shares are trading 0.92% higher at $73.80 in premarket on the last check Monday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in